<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="161322">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01748695</url>
  </required_header>
  <id_info>
    <org_study_id>V158866-2Pa-01</org_study_id>
    <nct_id>NCT01748695</nct_id>
  </id_info>
  <brief_title>A Safety, Tolerability and Efficacy Study of V158866 in Central Neuropathic Pain Following Spinal Cord Injury</brief_title>
  <official_title>A Phase IIa, Randomized, Double-blind, Placebo-controlled, Two-period Cross-over Study Evaluating the Safety, Tolerability and Efficacy of V158866 in Central Neuropathic Pain Following Spinal Cord Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vernalis (R&amp;D) Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate whether V158866 is safe and effective for the
      treatment of neuropathic pain due to spinal cord injury.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from baseline in mean pain intensity scores on the NRS.</measure>
    <time_frame>4 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary efficacy endpoint will be the comparison of the overall pain intensity on the NRS for the last 7 days of each treatment period. (V158866 compared to placebo)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of V158866 compared to placebo</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety and tolerability measured by:
Adverse events, Columbia Suicide Severity Rating Scale change from baseline, Vital signs change from baseline, 12-lead ECG change from baseline, Beck Depression Inventory change from baseline, Laboratory safety tests changes from baseline, ARC Inventory - marijuana change from baseline, RBANS change from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gracely pain scores</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Gracely pain scores will be compared between V158866 and placebo treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep interference</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Sleep interference scores will be compared between treatment with V158866 and placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative Sensory Testing</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Quantitative Sensory Testing parameters will be compared between treatment with V158866 and placebo</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Neuropathic Pain Due to Spinal Cord Injury</condition>
  <arm_group>
    <arm_group_label>Placebo followed by V158866</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo once per day for 4 weeks followed by V158866 450mg once per day for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>V158866 followed by Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>V158866 450mg once per day for 4 Weeks followed by Placebo once per day for 4 Weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>V158866</intervention_name>
    <arm_group_label>Placebo followed by V158866</arm_group_label>
    <arm_group_label>V158866 followed by Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo followed by V158866</arm_group_label>
    <arm_group_label>V158866 followed by Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  aged 18 - 65 years

          -  documented spinal cord injury at or below T5

          -  moderate pain at or below the level of the spinal cord injury for at least 3 months

          -  compliant with daily diary

          -  stable pain scores on the NRS

          -  mean pain intensity of at least 4 and not more than 9 on the NRS (or if the mean NRS
             score is &gt;9, the mean Gracely score must be â‰¤19)

        Exclusion Criteria:

          -  women of child-bearing potential

          -  men who intend to father a child

          -  a history of multiple drug allergies, hypersensitivity to any cannabinoid

          -  an increased risk of seizure

          -  evidence of depression and/or a score of &gt;19 on the BDI-II

          -  suicidal ideation or suicidal behavior in the past 10 years

          -  a history of substance abuse or dependence within the past year, excluding nicotine
             and caffeine

          -  a positive urine test for cannabis at screening

          -  taking excluded medications that cannot be stopped

          -  a positive pregnancy test
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine N Sang, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christine N Sang, MD, MPH</last_name>
    <email>csang@partners.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kierin O'Donnell</last_name>
    <email>paintrials@partners.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christine N Sang, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 14, 2014</lastchanged_date>
  <firstreceived_date>December 11, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Christine N. Sang, MD, MPH</investigator_full_name>
    <investigator_title>Dr Christine Sang</investigator_title>
  </responsible_party>
  <keyword>Neuropathic pain</keyword>
  <keyword>Spinal cord injury</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Spinal Cord Injuries</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
